Email Updates

Search form

You are here

22 December 2017 VOLUME 18 ISSUE 51

Media Coverage

  • The data is clear: it is possible to end the global AIDS pandemic. To do so, the international community must commit more resources to achieve the target of 90-90-90… While the reach of global AIDS programs to treat 21 million people is remarkable, there remain 17 million people living with the disease who are not yet on antiretroviral therapy.

    December 21, 2017
    OUP Blog
  • A new modeling study recently published in the Journal of Acquired Immune Deficiency Syndromes estimated that more than 30 percent of HIV infections in the United States could be prevented if at least 25 percent of men who have sex with men at risk for HIV receive pre-exposure prophylaxis, or PrEP. This estimate exceeds a goal set by the United States’ National HIV/AIDS Strategy to reduce 25 percent of new infections by 2020.

    December 21, 2017
    Healio
  • HPV infection can lead to anal cancer and it is estimated that men who have sex with men (MSM) are 20 times more likely to develop anal cancer than heterosexual men. In addition, the authors note that HIV-infected MSM are more likely to develop anal cancer than HIV-uninfected MSM, with incidence rates being approximately 80 times higher for HIV-infected MSM in comparison to HIV-uninfected men.

    December 21, 2017
    General, HPV Vaccines
    Contagion Live
  • While the effort to reduce the HIV transmission rate among men who have sex with men (MSM) will likely rely on a combination of measures, scale-up of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) on its own could prevent a substantial proportion of new cases.

    December 20, 2017
    POZ
  • Pharmaceutical giant Gilead, which manufactures the HIV anti-retroviral drug Truvada, has withdrawn its appeal against the High Court’s refusal to grant an injunction against generic manufacturers.

    December 20, 2017
    The Irish Times
  • Uganda and Kenya are among seven African countries carrying out large-scale clinical trials of a long-lasting injectable pre-exposure prophylaxis (PrEP) in sexually active women.The trials, called HPTN 084 and sponsored by the US National Institutes of Health, will also be conducted in Botswana, Malawi, Swaziland, South Africa and Zimbabwe and will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every eight weeks can safely protect women at risk of HIV infection.

    December 20, 2017
    The East African
  • By using the combination of biomarkers plus the diversity index we found that it was possible to be more accurate in identifying when someone got infected. This will help diagnose people in the early infection phase. This in turn will help health authorities target the high risk populations behind disproportionately higher rates of HIV transmission.

    December 20, 2017
    General
    The Independent
  • The new United States National Security Strategy, released Monday, outlines a US-centric development policy that prioritizes working with countries aligned with US interests, calls for countering China’s influence, views development as a tool for US security and puts private sector activity at the fore.

    December 19, 2017
    General
    Devex
  • The Centers for Disease Control and Prevention (CDC) currently recommends that everyone from ages 13 to 64 should be tested for HIV at least once. The U.S. Preventive Services Task Force advises that HIV testing discussions should start slightly later, at age 15. (People at higher risk—such as those who are sexually active, sexually active gay, bisexual and transgender people, and IV drug users—should be tested at least yearly.

    December 19, 2017
    General
    TIME
  • People with HIV who had high viral load were more likely to report vaginal or anal sex without a condom with a partner of unknown or different HIV status, a US study of people with detectable viral load has found.

    December 18, 2017
    General, Treatment
    aidsmap
  • President Donald Trump’s administration appears to have kicked up its own tumult by instructing the US Centers for Disease Control and Prevention (CDC) to avoid certain words in its 2019 budget request.

    December 18, 2017
    General
    Science Mag
  • Brazil recently became the first country in Latin America to roll out PrEP, the HIV prevention pill…. Over three weeks, the Hornet community was asked to participate — 3218 responses were collected. The findings will help us use data to inform the PrEP response, influence policy and mobilize the LGBTQ community.

    December 17, 2017
    Hornet App
  • Kenya has reported increased spending on initiatives to fight Aids in the last three years. In his World Aids Day speech, Health Cabinet Secretary Cleopa Mailu said expenditure on HIV programmes rose from Sh20.4 billion in 2014 to Sh26.4 billion last year.

    December 17, 2017
    Standard Media
  • Six short videos describe how a Kenyan nonprofit organization tackles one of Africa’s toughest missions: helping young women protect themselves against HIV.

    December 15, 2017
    The New York Times
  • One-in-four people in Lesotho lives with HIV -- the country with the highest new infection rate in the world. Although efforts to contain the epidemic have expanded in the last 12 years, poverty and more forces women to fight an uphill battle.

    December 12, 2017
    General, Treatment
    VICE
  • Most HIV-positive people in France under treatment take a daily dose of antiviral drugs for life. However, a major trial is currently underway that may confirm that patients could omit several days of treatment a week without risk to their health.

    November 30, 2017
    The Conversation

Published Research

Announcements

  • There will be no issue next week. The NewsDigest will return on January 5, 2017. Our best wishes for happy holidays and a peaceful new year, and our thanks for reading!

    December 22, 2017